Market revenue in 2023 | USD 11.0 million |
Market revenue in 2030 | USD 38.5 million |
Growth rate | 19.5% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.91% in 2023. Horizon Databook has segmented the Italy plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Small portion of the spending is also invested in R&D of therapies for chronic diseases such as cancers, cardiovascular diseases, and infectious diseases, like HIV & COVID-19. The presence of key players & their initiatives, such as investment & funding for expansion of pDNA manufacturing units, is also contributing to growth of the market in the country.
For instance, AGC Biologics, a top-tier global biopharmaceutical CDMO, announced the expansion of its CGT excellence center in Milan, Italy, to boost capacity and add viral vector suspension capabilities. The Milan site has unique processing & manufacturing experience and managed to produce two CGT products; it was the first GMP facility certified in Europe for ex-vivo gene therapy manufacturing.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Italy plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account